Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene

European Journal of Drug Metabolism and Pharmacokinetics
O SchusterH E Knoell

Abstract

In a pharmacokinetic study on 18 healthy male volunteers the bioavailability and elimination kinetics of furosemide-retard and the combination furosemide-retard/triamterene were investigated and compared with the non-retarded form and another retard form of furosemide. The relative bioavailability of the non-retarded form of furosemide was distinctly reduced by the retardation in the substances investigated. It varied between 42-66% in the plasma and between 37-73% in the urine. In the combination with triamterene the serum concentration time curve of furosemide was only slightly modified but the renal excretion of furosemide was more influenced (36% for furosemide-retard and 25% for furosemide-retard/triamterene). In comparison, the values for the renal excretion of triamterene and OH-TA sulfate were distinctly greater than those obtained after administration of triamterene alone. A renewed increase of the plasma concentration and renal excretion of furosemide were observed between 9 and 10.5 h after administration of furosemide-retard/triamterene. This observation suggests that a further absorption of furosemide occurs as a consequence of the delayed release from distal parts of the small intestine or from the large intestine.

References

Aug 1, 1979·European Journal of Clinical Pharmacology·U Gundert-RemyE Mutschler
Mar 1, 1979·Journal of Chromatography·S SvedI J McGilveray
May 1, 1977·Clinical Pharmacology and Therapeutics·A W PruittP G Dayton
Jan 1, 1977·Current Medical Research and Opinion·K MengF Hoffmeister
Oct 9, 1970·Deutsche medizinische Wochenschrift·K Meng
Jun 15, 1969·Klinische Wochenschrift·K Meng
Jan 1, 1984·European Journal of Clinical Pharmacology·D LoewH E Knoell
Nov 1, 1982·Clinical Pharmacology and Therapeutics·B Beermann
Oct 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·J HasegawaL Z Benet
Oct 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·P ChennavasinD C Brater
Aug 30, 1963·Deutsche medizinische Wochenschrift·H KLEINFELDER
Jun 15, 1964·Klinische Wochenschrift·F SUZUKIA HEIDLAND
Oct 1, 1964·Klinische Wochenschrift·P MUELLER, F SCHAUB
Nov 15, 1964·Klinische Wochenschrift·E BUCHBORN, S ANASTASAKIS

Citations

Jul 1, 1988·European Journal of Drug Metabolism and Pharmacokinetics·V HeimsothO Schuster
Jan 1, 1989·Pharmacology & Therapeutics·D A Joyce
Apr 1, 1991·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·J P GrotenP J van Bladeren
May 1, 1992·European Journal of Pharmacology·J P GrotenP J van Bladeren
May 15, 1996·Environmental Toxicology and Pharmacology·C TohyamaA Naganuma
Aug 13, 2009·Environmental Health Perspectives·Billy AmzalAgneta Akesson
Aug 19, 2014·Chemosphere·Lukasz J Binkowski, Katarzyna Sawicka-Kapusta
May 23, 2015·The Cochrane Database of Systematic Reviews·Vijaya M MusiniCiprian D Jauca

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Spatio-Temporal Regulation of DNA Repair

DNA repair is a complex process regulated by several different classes of enzymes, including ligases, endonucleases, and polymerases. This feed focuses on the spatial and temporal regulation that accompanies DNA damage signaling and repair enzymes and processes.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Separation Anxiety

Separation anxiety is a type of anxiety disorder that involves excessive distress and anxiety with separation. This may include separation from places or people to which they have a strong emotional connection with. It often affects children more than adults. Here is the latest research on separation anxiety.

KIF1A Associated Neurological Disorder

KIF1A associated neurological disorder (KAND) is a rare neurodegenerative condition caused by mutations in the KIF1A gene. KAND may present with a wide range and severity of symptoms including stiff or weak leg muscles, low muscle tone, a lack of muscle coordination and balance, and intellectual disability. Find the latest research on KAND here.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.